ARTICLE | Clinical News
VAS972: Began Feasibility Study
January 16, 2001 8:00 AM UTC
Vasogen Inc. (TSE:VAS; MEW), Toronto, Ontario Product: VAS972 Business: Autoimmune/Inflammation Therapeutic category: Immune modulation Target: Immune cells Description: Immune modulation therapy usi...